Pediatrix Medical Group (MD) Q2 2024 earnings summary

Executive summary

• Q2 2024 net loss was $153 million ($1.84 per share), driven by $154.2 million goodwill impairment and $192.9 million in total non-cash charges, as the company formalized a broad-based portfolio restructuring to exit most office-based and urgent care practices, focusing on hospital-based and maternal-fetal medicine services.

• Net revenue for Q2 2024 was $504.3 million, up 0.7% year-over-year, with growth from same-unit revenue and favorable payer mix, partially offset by practice dispositions.

• Adjusted EBITDA for Q2 2024 was $57.9 million, slightly down from $59.1 million in Q2 2023, with a one-time $3 million benefit from a payer settlement.

• Diluted EPS was $(1.84) versus $0.34 in Q2 2023; Adjusted EPS was $0.34, down from $0.39.

• Leadership changes include the appointment of a new CFO and Chief Administrative Officer, effective Q3 2024.

Financial highlights

• Six-month net revenue was $999.4 million, up 0.8% year-over-year, with same-unit net revenue up 2.9%.

• Operating cash flow in Q2 was $109 million, up from $93 million in the prior year.

• Cash and cash equivalents at June 30, 2024, were $19.4 million, down from $73.3 million at year-end 2023.

• Net debt position declined to roughly $600 million, with total debt outstanding at $622 million at quarter-end.

• DSO improved to 49.5 days at June 30, 2024, from 52 days at March 31.

Outlook and guidance

• Full-year 2024 Adjusted EBITDA guidance remains unchanged at $200–$220 million.

• Portfolio restructuring is expected to add approximately $30 million in annualized Adjusted EBITDA upon completion, with the positive impact fully realized in 2025.

• Management expects sufficient liquidity for working capital, acquisitions, capital expenditures, restructuring, share repurchases, and contractual obligations for at least the next 12 months.

• Exit from most office-based practices is expected to be completed by December 31, 2024.

• Adjusted EBITDA for the second half of 2024 is expected to be consistent between Q3 and Q4.